A second development program has been launched by Qiagen and HTG Molecular Diagnostics under a master assay development, commercialization and manufacturing deal that was announced last year. The program will include the development of gene expression profiling assays using HTG EdgeSeq technology to support the therapeutic development and commercialization programs of an unnamed pharmaceutical firm.
Qiagen, HTG Molecular announce 2nd development program
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.